Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced that Arctic Vision, Clearside’s partner, has successfully completed enrollment in its Phase 3 randomized, double-blind, placebo-controlled clinical trial in China for suprachoroidal use of ARCATUS^® (ARVN001) for the treatment of uveitic macular edema. Arctic Vision is a specialty ophthalmology company based in China that has the exclusive license for commercialization and development of XIPERE^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which they refer to as ARCATUS, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries.

“This achievement represents significant progress in expanding the global acceptance of our revolutionary suprachoroidal delivery platform,” said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside. “The continued development of ARCATUS by our partner, Arctic Vision, offers new hope to patients in China suffering from uveitic macular edema. As the clear leader in delivering drugs and drug candidates into the suprachoroidal space, our innovative, proprietary SCS Microinjector^® provides an in-office, nonsurgical, repeatable delivery option with a reliable and robust safety profile, based on thousands of SCS injections performed to date.”